logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Tag: Agenus (AGEN)

Prohost Letter #414

Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week in Review into the Prohost Letter this time. We thought it would be easier for the readers to get last week’s updates and comments...

Read More

October 25, 2017

0

Agenus: Signing a lucrative and rewarding agreement with Gilead

Agenus (AGEN) announced recently that it entered into an immuno-oncology (I-O) partnership with Gilead Sciences (GILD) . The partnership is focused on developing and commercializing up to five novel I-O  therapies. The terms of the agreement Agenus is entitled to...

Read More

December 20, 2018

0

Agenus fincances through Tokenization. Amgen's critics hit hard. Why BioTime could thrive on OncoCyte news

AGENUS Agenus (AGEN)  announced the upcoming launch of its Biotech Electronic Security Token (BEST);  the first digital security offering in healthcare. Tokenization enables qualified investors to directly invest in a single biotech product while preserving shareholder equity. Garo Armen, Chairman...

Read More

January 30, 2019

0

During the Departed Week

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week Highs The three picks referred to in the above title are, Novartis (NVS), Array (AARY) and Ionis (IONS) . Previous Prohost Letters discussed Novartis...

Read More

March 19, 2019

0

We Introduce UroGen Pharma and Discuss Its Pipeline of Products

Presenting UroGen Pharma UroGen Pharma ( URGN ) focuses on cancers and urologic diseases. It announced its fourth quarter and full-year ended December 31, 2019 financial results. The announcement started with Liz Barrett, President and Chief Executive Officer (CEO) of UroGen...

Read More

April 2, 2020

0

Agenus: Signing a lucrative and rewarding agreement with Gilead

Agenus (AGEN) announced recently that it entered into an immuno-oncology (I-O) partnership with Gilead Sciences (GILD) . The partnership is focused on developing and commercializing up to five novel I-O  therapies. The terms of the agreement Agenus is entitled to...

Read More

December 20, 2018

0

Agenus fincances through Tokenization. Amgen's critics hit hard. Why BioTime could thrive on OncoCyte news

AGENUS Agenus (AGEN)  announced the upcoming launch of its Biotech Electronic Security Token (BEST);  the first digital security offering in healthcare. Tokenization enables qualified investors to directly invest in a single biotech product while preserving shareholder equity. Garo Armen, Chairman...

Read More

January 30, 2019

0

The Time Has Come for Agenus to Excel. See Also: Why Evoke Pharma Traded UP Today

Agenus Has Two Separate Press Releases In the First Press Release from Agenus: Agenus ( AGEN ) announced that it will be making a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181 at the American Association...

Read More

June 22, 2020

0

During the Departed Week

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week Highs The three picks referred to in the above title are, Novartis (NVS), Array (AARY) and Ionis (IONS) . Previous Prohost Letters discussed Novartis...

Read More

March 19, 2019

0

We Introduce UroGen Pharma and Discuss Its Pipeline of Products

Presenting UroGen Pharma UroGen Pharma ( URGN ) focuses on cancers and urologic diseases. It announced its fourth quarter and full-year ended December 31, 2019 financial results. The announcement started with Liz Barrett, President and Chief Executive Officer (CEO) of UroGen...

Read More

April 2, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 11
  • 12
  • 13
  • 14
  • 15
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy